Viewing data from:

RAMIPRIL

ANDA

RAMIPRIL | A077626 | LUPIN LTD

4 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 12 NDCs

Highest NADAC/Unit

$0.0735

per ea

Lowest NADAC/Unit

$0.0474

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68180059110RAMIPRIL 10 MG CAPSULE	$0.0735	EA	Generic	—	2026-06-17
68180059109RAMIPRIL 10 MG CAPSULE	$0.0735	EA	Generic	—	2026-06-17
68180059101RAMIPRIL 10 MG CAPSULE	$0.0735	EA	Generic	—	2026-06-17
68180059102RAMIPRIL 10 MG CAPSULE	$0.0735	EA	Generic	—	2026-06-17
68180059009RAMIPRIL 5 MG CAPSULE	$0.0549	EA	Generic	—	2026-06-17
68180059001RAMIPRIL 5 MG CAPSULE	$0.0549	EA	Generic	—	2026-06-17

Showing 6 of 12 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain11 active DMFs8 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

EUROAPI GERMANY GMBHRAMIPRIL

DMF 152082000

DR REDDYS LABORATORIES LTDRAMIPRIL USP

DMF 161932002

NEULAND LABORATORIES LTDRAMIPRIL USP

DMF 166472003

CIPLA LTDRAMIPRIL USP

DMF 170332003

APITORIA PHARMA PRIVATE LTDRAMIPRIL USP

DMF 175702004

LUPIN LTDRAMIPRIL USP

DMF 180242005

HETERO LABS LTDRAMIPRIL

DMF 183382004

UNIMARK REMEDIES LTDRAMIPRIL USP

DMF 195222006

AARTI PHARMALABS LTDRAMIPRIL USP (GRADE A)

DMF 197142006

APOTEX PHARMACHEM INDIA PVT LTDRAMIPRIL USP

DMF 207132007

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDRAMIPRIL USP

DMF 246502011

ESTEVE QUIMICA SAInactiveRAMIPRIL

DMF 169002003

SMS PHARMACEUTICALS LTDInactiveRAMIPRIL

DMF 174012004

LUPIN LTDInactiveRAMIPRIL USP (PROCESS B)

DMF 179562004

AARTI INDUSTRIES LTDInactiveRAMIPRIL USP, GRADE II

DMF 197192006

RANBAXY LABORATORIES LTDInactiveRAMIPRIL

DMF 203802007

WATSON PHARMA PRIVATE LTDInactiveRAMIPRIL USP

DMF 214022008

MELODY HEALTHCARE PVT LTDInactiveRAMIPRIL

DMF 238852010

EUROAPI GERMANY GMBHInactiveRAMIPRIL (PROCESS 2)

DMF 375062022

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jun 10, 2008	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 1.25MG

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Jun 9, 2008

No patent or exclusivity listings for this strength.

#002 — 2.5MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 9, 2008

#003 — 5MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 9, 2008

#004 — 10MG

0 patents0 exclusivities▾

CAPSULE;ORAL | Approved: Jun 9, 2008